Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
Authors:
Top Cited Papers
- 10 February 2024
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 42 (5) , 571-583
Abstract
Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.Keywords
This publication has 33 references indexed in Scilit:
- Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision MakingJCO Precision Oncology, 2017
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionCancer Discovery, 2017
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA MutationNew England Journal of Medicine, 2017
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL StudyEuropean Urology, 2017
- DNA-Repair Defects and Olaparib in Metastatic Prostate CancerNew England Journal of Medicine, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2015
- Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate CancerJournal of Clinical Oncology, 2013
- Resistance to therapy caused by intragenic deletion in BRCA2Nature, 2008
- Correcting for non-compliance in randomized trials using rank preserving structural failure time modelsCommunications in Statistics - Theory and Methods, 1991